



MAYNE PHARMA EXECUTES LICENSE AND SUPPLY AGREEMENT WITH GALDERMA FOR GENERIC ORACEA®

- Builds on core strengths and broadens portfolio of dermatology products -
- Aligns with Company mission of expanding access to high quality medicines -

24 February 2023, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that one of its US subsidiaries has entered into a license and supply agreement with Galderma, the pure-play dermatology category leader, for an unbranded authorized generic version of ORACEA® (doxycycline) 40 mg capsules (30 mg immediate release / 10 mg delayed release) manufactured pursuant to NDA 050805 and indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. The agreement grants Mayne Pharma an exclusive three-year license of the authorized generic for the US market.

For calendar year 2022, the ORACEA® market was valued at approximately US\$210 million, according to IQVIA, a leading healthcare data and analytics provider.

Mayne Pharma's CEO Mr. Shawn O'Brien said: "This agreement provides another example of how we are building on our core strengths and expanding our portfolio of dermatology products. We continue to focus on identifying and taking advantage of strategic expansion opportunities, and generic ORACEA® fits well within our roster of products to help patients have healthier skin. Our goal, as always, is to ensure widespread access, reducing the burden on prescriber and patient ability to get high quality dermatology medications. This will allow us to drive revenue growth and deliver value to shareholders."

For further information contact:

Australia:
Craig Haskins
+61 421 029 843

ir@maynepharma.com

USA:
Lisa M. Wilson
T: 917-543-9932

E: ir@maynepharma.com

Authorised for release to the ASX by the Chair

ORACEA is a registered trademark of Galderma Holding S.A.

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia